Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2- dependent and-independent pathways

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Dong, Xiaofeng ^a   Li, Rui ^b   Xiu, Peng ^a   Dong, Xuesong ^c   Xu, Zongzhen ^a   Zhai, Bo ^c   Liu, Feng ^a   Jiang, Hongchi ^c   Sun, Xueying ^c,d   Li, Jie ^a   Qiao, Haiquan ^c  

^a SHANDONG UNIVERSITY   (China)

^b LIAOCHENG PEOPLE'S HOSPITAL   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLADENINE; BECLIN 1; CHLOROQUINE; CYCLOOXYGENASE 2; FAS LIGAND; GELATINASE A; MELOXICAM; PROSTAGLANDIN E2; PROTEIN BAX; PROTEIN KINASE B; PROTEIN MCL 1; SURVIVIN; UVOMORULIN; ANTINEOPLASTIC AGENT; CADHERIN; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGER2 PROTEIN, HUMAN; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CARCINOMA CELL; CELL ADHESION; CELL INVASION; CELL MIGRATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; UPREGULATION; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; GENETICS; LIVER TUMOR; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CADHERINS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; SIGNAL TRANSDUCTION; THIAZINES; THIAZOLES; TUMOR STEM CELL ASSAY;

EID: 84899785948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092864     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
3. Kern MA, Schoneweiss MM, Sahi D, Bahlo M, Haugg AM, et al. (2004) Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis; 25: 1193-1199. (Pubitemid 38968047)
4. Larkins TL, Nowell M, Singh S, Sanford GL (2006) Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 6: 181.
5. Banu SK, Lee J, Speights VO Jr, Starzinski-Powitz A, Arosh JA (2008) Cyclooxygenase-2 regulates survival, migration, and invasion of human endometriotic cells through multiple mechanisms. Endocrinology 149: 1180-1189. (Pubitemid 351397965)
6. Ali-Fehmi R, Morris RT, Bandyopadhyay S, Che M, Schimp V, et al. (2005) Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol 192: 819-825. (Pubitemid 40311275)
7. Rizzo MT (2011) Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 412(9-10): 671-687.
8. Li J, Chen X, Dong X, Xu Z, Jiang H, et al. (2006) Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Gastroenterol Hepatol 21: 1814-1820. (Pubitemid 44657002)
9. Jiang X, Li H, Qiao H, Jiang H, Xu R, et al. (2009) Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci 100: 2226-2233.
10. Sugimoto Y, Narumiya S (2007) Prostaglandin E receptors. J Biol Chem 282: 11613-11617. (Pubitemid 47100657)
11. Wang D, Mann JR, DuBois RN (2005) The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128: 1445-1461. (Pubitemid 40712194)
12. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, et al. (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc (Delta 716) knockout mice. Nat Med 7: 1048-1051. (Pubitemid 32937386)
13. Vo BT, Morton D Jr, Komaragiri S, Millena AC, Leath C, et al. (2013) TGF-beta effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology 154(5): 1768-1779.
14. Zhou L, Huang Y, Li J, Wang Z (2010) The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 27(2): 255-61.
15. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2(7): 489-501. (Pubitemid 37328931)
16. David R (2012) Metabolism: Keeping fit with autophagy. Nat Rev Mol Cell Biol 13(3): 136.
17. Codogno P, Mehrpour M, Proikas-Cezanne T (2012) Canonical and non-canonical autophagy: variations on a common theme of self-eating? Nat Rev Mol Cell Biol 13(1): 7-12.
18. Su M, Mei Y, Sinha S (2013) Role of the Crosstalk between Autophagy and Apoptosis in Cancer. J Oncol 2013: 102735.
19. Wei Z, Jiang X, Qiao H, Zhai B, Zhang L, et al. (2013) STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells. Cell Signal 25: 931-938.
20. Ma L, Qiao H, He C, Yang Q, Cheung CH, et al. (2012) Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer. Invest New Drugs 30(2): 508-517.
21. Xiu P, Dong X, Xu Z, Zhu H, Liu F, et al. (2013) Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Cancer Sci 104(3): 375-382.
22. He C, Sun XP, Qiao H, Jiang X, Wang D, et al. (2012) Downregulating hypoxia-inducible factor-2alpha improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma. Cancer Sci 103: 528-534.
23. Wang J, Ma Y, Jiang H, Zhu H, Liu L, et al. (2011) Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice. J Hepatol 55: 359-368.
24. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8: 741-752. (Pubitemid 47312826)
25. Kwon SH, Jeong SW, Jang JY, Lee JE, Lee SH, et al. (2012) Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma. Clin Mol Hepatol 18: 287-294.
26. Zhou L, Wang DS, Li QJ, Sun W, Zhang Y, et al. (2013) The Down-Regulation of Notch1 Inhibits the Invasion and Migration of Hepatocellular Carcinoma Cells by Inactivating the Cyclooxygenase-2/Snail/E-cadherin Pathway In Vitro. Dig Dis Sci 58(4): 1016-1025.
27. Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34. (Pubitemid 43723979)
28. Margineanu E, Cotrutz CE, Cotrutz C (2008) Correlation between E-cadherin abnormal expressions in different types of cancer and the process of metastasis. Rev Med Chir Soc Med Nat Iasi 112: 432-436.
29. Mima K, Hayashi H, Kuroki H, Nakagawa S, Okabe H, et al. (2013) Epithelial-mesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: Clinical significance of transforming growth factor-beta signaling. Oncol Lett 5: 149-154.
30. Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, et al. (2012) Activation of STAT3 signal pathway correlates with twist and E-cadherin expression in hepatocellular carcinoma and their clinical significance. J Surg Res 174:120-129.
31. Brouxhon SM, Kyrkanides S, Teng X, Athar M, Ghazizadeh S, et al. (2013) Soluble E-cadherin: a critical oncogene modulating recept or tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling. Oncogene doi: 10.1038/onc.2012.563.
32. Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, et al. (2006) Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 66: 5338-5345. (Pubitemid 43844959)
33. Jang TJ, Cha WH, Lee KS (2010) Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas. Virchows Arch 457: 319-328.
34. Grabowska MM, Day ML (2012) Soluble E-cadherin: more than a symptom of disease. Front Biosci 17: 1948-1964.
35. Lau MT, Leung PC (2012) The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett 326: 191-198.
36. Lau MT, Klausen C, Leung PC (2011) E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via beta-catenin-Egr1-mediated PTEN expression. Oncogene 30: 2753-2766.
37. Naruse T, Nishida Y, Hosono K, Ishiguro N (2006) Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 27: 584-592. (Pubitemid 43378898)
38. Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132: 27-42.
39. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, et al. (2009) Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16: 3-11.
40. Huang S, Sinicrope FA (2010) Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy 6: 256-269.
41. Liu D, Yang Y, Liu Q, Wang J (2011) Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells. Med Oncol 28: 105-111.
42. Amaravadi RK, Thompson CB (2007) The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 13: 7271-7279.
43. Kang R, Zeh HJ, Lotze MT, Tang D (2011) The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 18: 571-580.
44. Tanida I, Ueno T, Kominami E (2008) LC3 and autophagy. Methods Mol Biol 445: 77-88.